Oxford BioTherapeutics has entered a multi‑year collaboration with Bristol Myers Squibb to discover and develop novel T‑cell ...
Viridian Therapeutics has announced encouraging topline results from its REVEAL‑1 phase 3 clinical trial evaluating ...
GLP-1 therapies have now advanced far beyond their origins. Originally developed as treatments for type 2 diabetes, they have ...
For decades, progress in IVF has been driven by improvements in process efficiency rather than advances in biology. Clinics ...
For decades, MASLD has been described as a ‘silent’ condition because it rarely presents with dramatic liver specific ...
Kainova Therapeutics has dosed the first patient in the European expansion of its DOMISOL phase 1/2 trial of DT 7012, a ...
Announcing the approval, UCB said Kygevvi is a 2g/2g powder for oral solution and represents the first therapy available in the European Union beyond supportive care. The company noted that TK2d ...
Subcutaneous delivery shows IV‑level efficacy in moderate to severe TED Amgen has announced positive topline findings from a phase 3 study evaluating a subcutaneous formulation of Tepezza in adults ...
Kenneth Hobby, President of Cure SMA, said: “Nearly ten years ago, the approval of Spinraza marked a turning point in SMA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results